Table 2 Vaccine characteristics and immunisation strategies considered in the models evaluating routine varicella vaccination

Banz et al. [35]

15 months; 11–12 years

86 %

0.5 %

85 % (children); 30 % (adolescents)

EUR 65.93 (children)^a; EUR 71.38 (adolescents)^a

Banz et al. [51]

1-2 years; 11–15 years

95 %

0.5 %

70 % (children); 85 % (adolescents)

EUR 42.20 (children)^a; EUR 56.65 (adolescents)^a

Beutels et al. [37]

15 months; 12 years

90 %

Waning in 15 % of the protected vaccinees^b

70 %

EUR 50.82^a

Bilcke et al. [30]

1 year (1st dose); 4, 6 or 11 years (2nd dose)

Data from van Hoek et al. 2012

Data from van Hoek et al. 2012

50 % or 95 % (1st dose); 50 %, 80 % or 90 % (2nd dose)

EUR 44.92^a

Bonanni et al. [36]

12-18 months; 13 years

90 % (1st dose); 93 % (2nd dose)

3 %

85 %

EUR 46.81^a,c

Brisson et al. [31]

12 months; 12 years

93 %

3.1 %

90 % (infants); 80 % (adolescents)

EUR 51.42 (children)^a; EUR 68.57 (adolescents)^a

Brisson et al. [32]

Infants; 11 years

93 %

3.1 %

90 % (infants); 80 % (adolescents)

EUR 44.32 (children)^a; EUR 59.10 (adolescents)^a

Coudeville et al. [52]

<6 years

90 %

Waning in 15 % of the protected vaccinees^b

80 %

EUR 18.11^c,d

Coudeville et al. [53]

12-36 months

97 %

3.1 %

45 %-90 %

EUR 52.00^a,c

Coudeville et al. [54]

12-36 months

97 %

3.1 %

45 %-90 %

EUR 64.08 (Germany)^a,c; EUR 59.56 (France)^a,c

Diez Domingo et al. [55]

15 months

90 %

No waning

95 %

EUR 37.11

Getsios et al. [56]

12 months

90 %

Waning in 15 % of the protected vaccinees^b

85 %

EUR 60.25^a,d

Ginsberg & Somekh [57]

12 months

87.6 %

3.1 %

94 %

EUR 8.01^a,c,d

Hammerschmidt et al. [58]

11-23 months (catch-up of 2–17 year olds)

86 % (1-dose schedule); 95 % (2-dose schedule)

0.5 %

90 % (1st dose); 80 % (2nd dose); 30 % (catch-up); 10 % (comparator)

EUR 47.38 (monovalent vaccine); EUR 47.92 (varicella-attributable cost of the MMRV vaccine)

Huse et al. [59]

15 months

95 %

No waning

Not specified

EUR 62.31^a

Lenne et al. [60]

1-2 years

97 %

3,1 %

97,15 %

EUR 42.54^a

Lieu et al. [61]

<6 years

90 %

Waning in 15 % of the protected vaccinees^b

97 %

EUR 54.12^a

Preblud et al. [62]

15 months

90 %

No waning

90 %

EUR 25.53

Scuffham et al. [63]

15 months

95 %

No waning

80 %; 10 % (comparator)

EUR 45.94

Scuffham et al. [34]

12 months; 12 years

95 %

No waning

80 % (infants); 50-75 % (adolescents)

EUR 42.26

Thiry et al. [64]

11 years

93,12 %

3.1 %

60 %

EUR 52.36^a

van Hoek et al. [33]

1 year (1st dose); 3 years (2nd dose)

89-96 % (1st dose); 93-96 % (2nd dose)

1.5-6.7 % (1st dose); 0.05-2.6 % (2nd dose)

90 % (1st dose); 80 % (2nd dose)

EUR 41.19

Zhou et al. [29]

Children

80 % (1-dose schedule)^e; 93 % (2-dose schedule)

No waning

Age-specific coverage rates; 95 % (2nd dose)

EUR 49.90 (monovalent vaccine)^f; EUR 65.64 (MMRV vaccine)^f